These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 24099590)
1. Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor. van Midwoud PM; Sturla SJ Chem Res Toxicol; 2013 Nov; 26(11):1674-82. PubMed ID: 24099590 [TBL] [Abstract][Full Text] [Related]
2. Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities. Pietsch KE; van Midwoud PM; Villalta PW; Sturla SJ Chem Res Toxicol; 2013 Jan; 26(1):146-55. PubMed ID: 23227857 [TBL] [Abstract][Full Text] [Related]
3. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. Gong J; Vaidyanathan VG; Yu X; Kensler TW; Peterson LA; Sturla SJ J Am Chem Soc; 2007 Feb; 129(7):2101-11. PubMed ID: 17256933 [TBL] [Abstract][Full Text] [Related]
4. Quantitative correlation of drug bioactivation and deoxyadenosine alkylation by acylfulvene. Neels JF; Gong J; Yu X; Sturla SJ Chem Res Toxicol; 2007 Oct; 20(10):1513-9. PubMed ID: 17900171 [TBL] [Abstract][Full Text] [Related]
5. Modulation of Cytotoxicity by Transcription-Coupled Nucleotide Excision Repair Is Independent of the Requirement for Bioactivation of Acylfulvene. Otto C; Spivak G; Aloisi CM; Menigatti M; Naegeli H; Hanawalt PC; Tanasova M; Sturla SJ Chem Res Toxicol; 2017 Mar; 30(3):769-776. PubMed ID: 28076683 [TBL] [Abstract][Full Text] [Related]
6. Base excision repair as a therapeutic target in colon cancer. Liu L; Nakatsuru Y; Gerson SL Clin Cancer Res; 2002 Sep; 8(9):2985-91. PubMed ID: 12231545 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of RNA polymerase II stalling by DNA alkylation. Malvezzi S; Farnung L; Aloisi CMN; Angelov T; Cramer P; Sturla SJ Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12172-12177. PubMed ID: 29087308 [TBL] [Abstract][Full Text] [Related]
9. Repair kinetics of acrolein- and (E)-4-hydroxy-2-nonenal-derived DNA adducts in human colon cell extracts. Choudhury S; Dyba M; Pan J; Roy R; Chung FL Mutat Res; 2013; 751-752():15-23. PubMed ID: 24113140 [TBL] [Abstract][Full Text] [Related]
10. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995 [TBL] [Abstract][Full Text] [Related]
11. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295 [TBL] [Abstract][Full Text] [Related]
12. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Jiang H; Yang LY Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501 [TBL] [Abstract][Full Text] [Related]
13. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Spencer DM; Bilardi RA; Koch TH; Post GC; Nafie JW; Kimura K; Cutts SM; Phillips DR Mutat Res; 2008 Feb; 638(1-2):110-21. PubMed ID: 17961607 [TBL] [Abstract][Full Text] [Related]
14. Immunological and mass spectrometry-based approaches to determine thresholds of the mutagenic DNA adduct O Kraus A; McKeague M; Seiwert N; Nagel G; Geisen SM; Ziegler N; Trantakis IA; Kaina B; Thomas AD; Sturla SJ; Fahrer J Arch Toxicol; 2019 Feb; 93(2):559-572. PubMed ID: 30446773 [TBL] [Abstract][Full Text] [Related]
16. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203 [TBL] [Abstract][Full Text] [Related]
17. Alteration in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove. Brooks N; McHugh PJ; Lee M; Hartley JA Chem Biol; 2000 Sep; 7(9):659-68. PubMed ID: 10980446 [TBL] [Abstract][Full Text] [Related]
18. Chromium(VI) enhances (+/-)-anti-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-induced cytotoxicity and mutagenicity in mammalian cells through its inhibitory effect on nucleotide excision repair. Hu W; Feng Z; Tang MS Biochemistry; 2004 Nov; 43(44):14282-9. PubMed ID: 15518579 [TBL] [Abstract][Full Text] [Related]
19. Nucleotide excision repair functions in the removal of chromium-induced DNA damage in mammalian cells. O'Brien TJ; Brooks BR; Patierno SR Mol Cell Biochem; 2005 Nov; 279(1-2):85-95. PubMed ID: 16283517 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Liu L; Gerson SL Curr Opin Investig Drugs; 2004 Jun; 5(6):623-7. PubMed ID: 15242251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]